Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01897701
Other study ID # NVX900.PH7.101
Secondary ID
Status Completed
Phase Phase 1
First received July 9, 2013
Last updated October 10, 2014
Start date July 2013
Est. completion date August 2014

Study information

Verified date October 2014
Source Novavax
Contact n/a
Is FDA regulated No
Health authority Australia: Department of Health and Ageing Therapeutic Goods Administration
Study type Interventional

Clinical Trial Summary

This is a randomized, observer-blinded, placebo-controlled trial in adults ≥18 years old. Randomization will be stratified by age (18 to 49 years and ≥50 years) and by prior influenza immunization within the past three months. Proportions of subjects in the various strata will not be pre-specified; rather, the goal will be to achieve an approximately equal distribution of subjects with these characteristics across the various treatment groups.

Treatments will comprise two identical IM doses at a 21-day interval (Day 0 and Day 21), in alternate deltoids. For each subject, study follow-up will span approximately 385 days total, or approximately 13 months from the first dose.


Recruitment information / eligibility

Status Completed
Enrollment 280
Est. completion date August 2014
Est. primary completion date August 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

Subjects must meet all of the following to be eligible for participation in the study:

1. Healthy adult male or female, =18 years of age,

2. Willing and able to give informed consent prior to study enrollment,

3. Able to comply with study requirements, and

4. Women of childbearing potential must have a negative urine pregnancy test prior to each vaccination, will be advised through the Informed Consent process to avoid becoming pregnant over the duration of the study, and must assert that they will employ an effective form of birth control for the duration of the study. Acceptable forms of birth control are: credible history of continuous abstinence from heterosexual activity or prior surgical sterilization, hormonal contraceptives (oral, injectable, implant, patch, ring), barrier contraceptives (condom or diaphragm), and intrauterine device (IUD). Women with an adequately documented history of surgical sterility, or =50 years of age and without menses for = 1 year are exempt from urine pregnancy testing.

Exclusion Criteria:

Subjects meeting any of the following criteria are not eligible for participation in the study.

1. Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care.

- Asymptomatic conditions or findings (e.g., mild hypertension, dyslipidemia) that are not associated with evidence of end-organ damage are not exclusionary provided that they are being appropriately managed and are clinically stable (i.e., unlikely to result in symptomatic illness within the time-course of this study) in the opinion of the investigator.

- Note that illnesses or conditions may be exclusionary, even if otherwise stable, due to therapies used to treat them (see exclusion criteria 2, 5, 7, 8).

2. Participation in research involving investigational product (drug / biologic / device) within 45 days before planned date of first vaccination.

3. History of a serious reaction to prior influenza vaccination.

4. History of Guillain-Barré Syndrome (GBS) within 6 weeks following a previous influenza vaccine.

5. Received any vaccine in the 4 weeks preceding the study vaccination; or any A(H7N9) avian influenza vaccine at any time.

6. Any known or suspected immunosuppressive condition, acquired or congenital, as determined by history and/or physical examination.

7. Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the study vaccine. An immunosuppressant dose of glucocorticoid will be defined as a systemic dose =10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted.

8. Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the study vaccine or during the study.

9. Acute disease at the time of enrollment (defined as the presence of a moderate or severe illness with or without fever, or an oral temperature >38.0°C on the planned day of vaccine administration).

10. Known disturbance of coagulation.

11. Women who are pregnant or breastfeeding, or plan to become pregnant during the study.

12. Suspicion or recent history (within one year of planned vaccination) of alcohol or other substance abuse.

13. Any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled or could interfere with evaluation of the vaccine or interpretation of study results (including neurologic or psychiatric conditions deemed likely to impair the quality of safety reporting).

14. Persons employed in a capacity that involves handling poultry or wild birds.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Biological:
Monovalent Avian Influenza VLP (H7N9)

Adjuvant 1

Placebo


Locations

Country Name City State
Australia CMAX Adelaide South Australia
Australia Q-Pharm Pty Limited Herston Queensland
Australia Linear Clinical Research Nedlands Western Australia

Sponsors (1)

Lead Sponsor Collaborator
Novavax

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of Safety Number (and percentages) of subjects with solicited local and systemic AEs over the seven days post-injection and all adverse events, solicited and unsolicited, including adverse changes in clinical laboratory parameters, over 35 days post-first injection.
Significant New Medical Conditions, Medically Attended Events and Serious Adverse Events will be collected for one year post-second injection.
Day 0 to Day 384 Yes
Primary Immunogenicity as assessed by hemagglutination-inhibiting (HAI) antibody titers against the vaccine-homologous A/Anhui/1/13 (H7N9) virus. Geometric mean titer (GMT)
Geometric mean ratio (GMR)
Seroconversion rate (SCR)
Seroresponse rate (SRR)
Day 0 to Day 384 No
Secondary Immunogenicity as assessed by neuraminidase-inhibiting antibodies to N9. Day 0 to Day 384 No
See also
  Status Clinical Trial Phase
Completed NCT01698060 - Immunogenicity of ND1.1 by Delivery Directly to the Ileum Phase 1
Completed NCT02213354 - H7N9 Mix and Match With MF59 in Healthy Elderly Persons Phase 2
Completed NCT02295813 - Safety and Pharmacokinetics Study of FBF001 Phase 1
Completed NCT00561184 - Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza Vaccine Phase 2
Completed NCT02921997 - H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses Phase 2
Completed NCT03682120 - Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza Phase 2
Completed NCT00895544 - Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in Adults Phase 1/Phase 2
Completed NCT02251288 - A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine Phase 1
Completed NCT02612909 - A Safety and Immunogenicity Study of IVACFLU-A/H5N1 Phase 2/Phase 3
Completed NCT02229357 - Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine Phase 2
Completed NCT01150552 - Studies of Avian Influenza Transmission to Humans in Egypt N/A
Completed NCT03472976 - H5N1 With or Without Topical Aldara in Healthy Adults Phase 1
Completed NCT01107262 - Avian Influenza Studies In Lebanon N/A
Completed NCT02839330 - A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age Phase 3
Completed NCT03014310 - H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology Phase 1
Completed NCT00298233 - High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza Phase 2
Completed NCT03318315 - Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4 Phase 2
Completed NCT03312231 - Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly Phase 2
Completed NCT03738241 - 2017 A/H7N9 IIV Revaccination Phase 2
Completed NCT03589807 - 2013/2017 H7N9 Prime-Boost Interval Phase 2

External Links